• 1
    van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J, Rawstron A, Asnafi V, Lecrevisse Q, Lucio P, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012;26:19081975.
  • 2
    Bene MC, Nebe T, Bettelheim P, Buldini B, Bumbea H, Kern W, Lacombe F, Lemez P, Marinov I, Matutes E, et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: A consensus proposal of the European LeukemiaNet Work Package 10. Leukemia 2011;25:567574.
  • 3
    Wood BL, Arroz M, Barnett D, DiGiuseppe J, Greig B, Kussick SJ, Oldaker T, Shenkin M, Stone E, Wallace P. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: Optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom 2007;72 Suppl 1:S1422.
  • 4
    Ruiz-Arguelles A, Rivadeneyra-Espinoza L, Duque RE, Orfao A. Report on the second Latin American consensus conference for flow cytometric immunophenotyping of hematological malignancies. Cytometry B Clin Cytom 2006;70:3944.
  • 5
    Haycocks NG, Lawrence L, Cain JW, Zhao XF. Optimizing antibody panels for efficient and cost-effective flow cytometric diagnosis of acute leukemia. Cytometry B Clin Cytom 2011;80:221229.
  • 6
    Kita K, Nakase K, Miwa H, Masuya M, Nishii K, Morita N, Takakura N, Otsuji A, Shirakawa S, Ueda T, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: Frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood 1992;80:470477.
  • 7
    Tiacci E, Pileri S, Orleth A, Pacini R, Tabarrini A, Frenguelli F, Liso A, Diverio D, Lo-Coco F, Falini B. PAX5 expression in acute leukemias: Higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. Cancer Res 2004;64:73997404.
  • 8
    Asnafi V, Beldjord K, Garand R, Millien C, Bahloul M, LeTutour P, Douay L, Valensi F, Macintyre E. IgH DJ rearrangements within T-ALL correlate with cCD79a expression, an immature/TCRgammadelta phenotype and absence of IL7Ralpha/CD127 expression. Leukemia 2004;18:19972001.
  • 9
    Macedo A, Orfao A, Vidriales MB, Lopez-Berges MC, Valverde B, Gonzalez M, Caballero MD, Ramos F, Martinez M, Fernandez-Calvo J, et al. Characterization of aberrant phenotypes in acute myeloblastic leukemia. Ann Hematol 1995;70:189194.
  • 10
    Dworzak MN, Fritsch G, Froschl G, Printz D, Gadner H. Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny. Blood 1998;92:32033209.
  • 11
    Lucio P, Parreira A, van den Beemd MW, van Lochem EG, van Wering ER, Baars E, Porwit-MacDonald A, Bjorklund E, Gaipa G, Biondi A, et al. Flow cytometric analysis of normal B cell differentiation: A frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia 1999;13:419427.
  • 12
    Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: The guardian of B cell identity and function. Nat Immunol 2007;8:463470.
  • 13
    Cavalcanti Junior GB, Savino W, Pombo-de-Oliveira MS. CD44 expression in T-cell lymphoblastic leukemia. Braz J Med Biol Res 1994;27:22592266.
  • 14
    Porwit-MacDonald A, Bjorklund E, Lucio P, van Lochem EG, Mazur J, Parreira A, van den Beemd MW, van Wering ER, Baars E, Gaipa G, et al. BIOMED-1 concerted action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia 2000;14:816825.
  • 15
    Hussein S, Gill KZ, Sireci AN, Colovai AI, Small T, Emmons FN, Murty VV, Bhagat G, Alobeid B. Aberrant T-cell antigen expression in B lymphoblastic leukaemia. Br J Haematol 2011;155:449456.
  • 16
    Gassmann W, Loffler H. Acute megakaryoblastic leukemia. Leuk Lymphoma 1995;18 Suppl 1:6973.
  • 17
    Orfao A, Ortuno F, de Santiago M, Lopez A, San Miguel J. Immunophenotyping of acute leukemias and myelodysplastic syndromes. Cytometry Part A 2004;58A:6271.
  • 18
    Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van't Veer MB. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9:17831786.
  • 19
    Costa ES, Thiago LS, Otazu IB, Ornellas MH, Land MG, Orfao A. An uncommon case of childhood biphenotypic precursor-B/T acute lymphoblastic leukemia. Pediatr Blood Cancer 2008;50:941942.
  • 20
    Ciudad J, Orfao A, Vidriales B, Macedo A, Martinez A, Gonzalez M, Lopez-Berges MC, Valverde B, San Miguel JF. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: Implications for minimal residual disease detection. Haematologica 1998;83:10691075.
  • 21
    van Lochem EG, van der Velden VH, Wind HK, te Marvelde JG, Westerdaal NA, van Dongen JJ. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: Reference patterns for age-related changes and disease-induced shifts. Cytometry B Clin Cytom 2004;60:113.
  • 22
    Patkar N, Alex AA, B B, Ahmed, R, Abraham A, George B, Vishwabandya A, Srivastava A, Mathews V. Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country. Cytometry B Clin Cytom 2012;82:252258.
  • 23
    Escribano L, Diaz-Agustin B, Lopez A, Nunez Lopez R, Garcia-Montero A, Almeida J, Prados A, Angulo M, Herrero S, Orfao A. Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin Cytom 2004;58:18.
  • 24
    Han K, Kim Y, Lee J, Lim J, Lee KY, Kang CS, Kim WI, Kim BK, Shim SI, Kim SM. Human basophils express CD22 without expression of CD19. Cytometry 1999;37:178183.
  • 25
    Martin-Martin L, Almeida J, Hernandez-Campo PM, Sanchez ML, Lecrevisse Q, Orfao A. Immunophenotypical, morphologic, and functional characterization of maturation-associated plasmacytoid dendritic cell subsets in normal adult human bone marrow. Transfusion 2009;49:16921708.
  • 26
    Kalina T, Vaskova M, Mejstrikova E, Madzo J, Trka J, Stary J, Hrusak O. Myeloid antigens in childhood lymphoblastic leukemia: Clinical data point to regulation of CD66c distinct from other myeloid antigens. BMC Cancer 2005;5:38.
  • 27
    Owaidah TM, Rawas FI, Al Khayatt MF, Elkum NB. Expression of CD66c and CD25 in acute lymphoblastic leukemia as a predictor of the presence of BCR/ABL rearrangement. Hematol Oncol Stem Cell Ther 2008;1:3437.
  • 28
    Tabernero MD, Bortoluci AM, Alaejos I, Lopez-Berges MC, Rasillo A, Garcia-Sanz R, Garcia M, Sayagues JM, Gonzalez M, Mateo G, et al. Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expresssion. Leukemia 2001;15:406414.
  • 29
    Alves GV, Fernandes AL, Freire JM, Paiva Ade S, Vasconcelos RC, Sales VS, Lemos TM, Gil EA, Freire FH, Cavalcanti e Silva DG, et al. Flow cytometry immunophenotyping evaluation in acute lymphoblastic leukemia: Correlation to factors affecting clinic outcome. J Clin Lab Anal 2012;26:431440.
  • 30
    Veltroni M, De Zen L, Sanzari MC, Maglia O, Dworzak MN, Ratei R, Biondi A, Basso G, Gaipa G. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: Implications for the detection of minimal residual disease in acute lymphocytic leukemia. Haematologica 2003;88:12451252.
  • 31
    Chen JS, Coustan-Smith E, Suzuki T, Neale GA, Mihara K, Pui CH, Campana D. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood 2001;97:21152120.
  • 32
    Gleissner B, Goekbuget N, Rieder H, Arnold R, Schwartz S, Diedrich H, Schoch C, Heinze B, Fonatsch C, Bartram CR, et al. CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: Results of the German Multicenter Trials for Adult ALL (GMALL). Blood 2005;106:40544056.
  • 33
    Ludwig WD, Rieder H, Bartram CR, Heinze B, Schwartz S, Gassmann W, Loffler H, Hossfeld D, Heil G, Handt S, et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: Results of the German multicenter trials GMALL 03/87 and 04/89. Blood 1998;92:18981909.
  • 34
    Hrusak O, Porwit-MacDonald A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 2002;16:12331258.
  • 35
    Borowitz MJ, Chan JKC. B lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities. In: Swerdlow SH, Campo EH, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: International Agency for Research on Cancer; 2008. p 171175.
  • 36
    Gorczyca W, Tugulea S, Liu Z, Li X, Wong JY, Weisberger J. Flow cytometry in the diagnosis of mediastinal tumors with emphasis on differentiating thymocytes from precursor T-lymphoblastic lymphoma/leukemia. Leuk Lymphoma 2004;45:529538.
  • 37
    Pilozzi E, Pulford K, Jones M, Muller-Hermelink HK, Falini B, Ralfkiaer E, Pileri S, Pezzella F, De Wolf-Peeters C, Arber D, et al. Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. J Pathol 1998;186:140143.
  • 38
    Borowitz MJ, Chan JKC. T lymphoblastic leukaemia/lymphoma. In: Swerdlow SH, Campo EH, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: International Agency for Research on Cancer; 2008. p 176178.
  • 39
    Khalidi HS, Chang KL, Medeiros LJ, Brynes RK, Slovak ML, Murata-Collins JL, Arber DA. Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. Am J Clin Pathol 1999;111:467476.
  • 40
    Uckun FM, Gaynon PS, Sensel MG, Nachman J, Trigg ME, Steinherz PG, Hutchinson R, Bostrom BC, Sather HN, Reaman GH. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: A Children's Cancer Group study. J Clin Oncol 1997;15:22142221.
  • 41
    Spits H, Lanier LL, Phillips JH. Development of human T and natural killer cells. Blood 1995;85:26542670.
  • 42
    Sandes AF, Castro IN, Miura TE, Maekawa YH, Cozac AP, Chauffaille ML, Rizzatti EG. Bone marrow infiltration by cells resembling plasmablasts in a patient with blastic plasmacytoid dendritic cell neoplasm. J Hematopathol 2011;4:123126.
  • 43
    Baer MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, Davey FR, Schiffer CA, Bloomfield CD. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 1997;90:16431648.
  • 44
    Ferreira-Facio CS, Milito C, Botafogo V, Fontana M, Thiago LS, Oliveira E, da Rocha-Filho AS, Werneck F, Forny DN, Dekermacher S, et al. Contribution of multiparameter flow cytometry immunophenotyping to the diagnostic screening and classification of pediatric cancer. PLoS One 2013;8:e55534.
  • 45
    Borowitz MJ, Bene MC, Harris NL, Porwit A, Matutes E. Acute leukaemias of ambiguous lineage. In: Swerdlow SH, Campo EH, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon: International Agency for Research on Cancer; 2008. p 150155.
  • 46
    Lhermitte L, de Labarthe A, Dupret C, Lapillonne H, Millien C, Landman-Parker J, Hermine O, Baruchel A, Sigaux F, Macintyre E, et al. Most immature T-ALLs express Ra-IL3 (CD123): Possible target for DT-IL3 therapy. Leukemia 2006;20:19081910.
  • 47
    Asnafi V, Buzyn A, Thomas X, Huguet F, Vey N, Boiron JM, Reman O, Cayuela JM, Lheritier V, Vernant JP, et al. Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: A LALA-94 study. Blood 2005;105:30723078.
  • 48
    Czuczman MS, Dodge RK, Stewart CC, Frankel SR, Davey FR, Powell BL, Szatrowski TP, Schiffer CA, Larson RA, Bloomfield CD. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: Cancer and leukemia Group B study 8364. Blood 1999;93:39313939.
  • 49
    Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, Ferrando A, Fielding AK, Goldstone AH, Ketterling RP, et al. T-cell acute lymphoblastic leukemia in adults: Clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood 2009;114:51365145.
  • 50
    Vitale A, Guarini A, Ariola C, Mancini M, Mecucci C, Cuneo A, Pane F, Saglio G, Cimino G, Tafuri A, et al. Adult T-cell acute lymphoblastic leukemia: Biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood 2006;107:473479.
  • 51
    Weiss LM, Bindl JM, Picozzi VJ, Link MP, Warnke RA. Lymphoblastic lymphoma: An immunophenotype study of 26 cases with comparison to T cell acute lymphoblastic leukemia. Blood 1986;67:474478.
  • 52
    Patel JL, Smith LM, Anderson J, Abromowitch M, Campana D, Jacobsen J, Lones MA, Gross TG, Cairo MS, Perkins SL. The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: A Children's Oncology Group report. Br J Haematol 2012;159:454461.
  • 53
    Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, Cheng C, Su X, Rubnitz JE, Basso G, et al. Early T-cell precursor leukaemia: A subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009;10:147156.
  • 54
    Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012;481:157163.
  • 55
    Vardiman JW, Brunning R, Arber D, LeBeau MM, Porwit A, Tefferi A, Bloomfield CD, Thiele J. Introduction and overview of the classification of the myeloid neoplasms. In: Swerdlow SH, Campo EH, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon: International Agency for Research on Cancer; 2008. p 1830.
  • 56
    San Miguel JF, Vidriales MB, Lopez-Berges C, Diaz-Mediavilla J, Gutierrez N, Canizo C, Ramos F, Calmuntia MJ, Perez JJ, Gonzalez M, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001;98:17461751.
  • 57
    Buccisano F, Maurillo L, Spagnoli A, Del Principe MI, Fraboni D, Panetta P, Ottone T, Consalvo MI, Lavorgna S, Bulian P, et al. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood 2010;116:22952303.
  • 58
    Pereira FG, Metze K, Costa FP, Lima CS, Lorand-Metze I. Phenotypic quantitative features of patients with acute myeloid leukemia. Neoplasma 2006;53:155160.
  • 59
    Sandes AF, Kerbauy DM, Matarraz S, Chauffaille Mde L, Lopez A, Orfao A, Yamamoto M. Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes. Cytometry B Clin Cytom 2013;84:157166.
  • 60
    Bahia DM, Yamamoto M, Chauffaille Mde L, Kimura EY, Bordin JO, Filgueiras MA, Kerbauy J. Aberrant phenotypes in acute myeloid leukemia: A high frequency and its clinical significance. Haematologica 2001;86:801806.
  • 61
    Bahia Kerbauy DM, Kimura EY, Chauffaille ML, Bordin JO, Kerbauy J, Yamamoto M. The singular value of CD34 and CD117 expression for minimal residual disease detection in AML. Leuk Res 2003;27:10691070.
  • 62
    Buhring HJ, Muller T, Herbst R, Cole S, Rappold I, Schuller W, Zhu X, Fritzsch U, Faul C, Armeanu S, et al. The adhesion molecule E-cadherin and a surface antigen recognized by the antibody 9C4 are selectively expressed on erythroid cells of defined maturational stages. Leukemia 1996;10:106116.
  • 63
    Thiago LS, Sandes AF. Diagnostic Challenges of CD4+/CD56+/CD123+ hematological neoplasms. An Bras Dermatol 2013;88:679.
  • 64
    Bueno C, Montes R, Martin L, Prat I, Hernandez MC, Orfao A, Menendez P. NG2 antigen is expressed in CD34+ HPCs and plasmacytoid dendritic cell precursors: Is NG2 expression in leukemia dependent on the target cell where leukemogenesis is triggered? Leukemia 2008;22:14751478.
  • 65
    Bueno C, Almeida J, Lucio P, Marco J, Garcia R, de Pablos JM, Parreira A, Ramos F, Ruiz-Cabello F, Suarez-Vilela D, et al. Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica 2004;89:5869.
  • 66
    Staal-Viliare A, Latger-Cannard V, Didion J, Gregoire MJ, Lecompte T, Jonveaux P, Rio Y. CD203c /CD117-, an useful phenotype profile for acute basophilic leukaemia diagnosis in cases of undifferentiated blasts. Leuk Lymphoma 2007;48:439441.
  • 67
    Hurwitz CA, Raimondi SC, Head D, Krance R, Mirro J Jr., Kalwinsky DK, Ayers GD, Behm FG. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood 1992;80:31823188.
  • 68
    Haas OA, Koller U, Grois N, Nowotny H. Immunophenotype of hematologic neoplasms with a translocation t(8;21). Recent Results Cancer Res 1993;131:361368.
  • 69
    Orfao A, Chillon MC, Bortoluci AM, Lopez-Berges MC, Garcia-Sanz R, Gonzalez M, Tabernero MD, Garcia-Marcos MA, Rasillo AI, Hernandez-Rivas J, et al. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements. Haematologica 1999;84:405412.
  • 70
    Petrovici K, Graf M, Hecht K, Reif S, Pfister K, Schmetzer H. Use of NG2 (7.1) in AML as a tumor marker and its association with a poor prognosis. Cancer Genomics Proteomics 2010;7:173180.
  • 71
    Munoz L, Nomdedeu JF, Villamor N, Guardia R, Colomer D, Ribera JM, Torres JP, Berlanga JJ, Fernandez C, Llorente A, et al. Acute myeloid leukemia with MLL rearrangements: Clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. Leukemia 2003;17:7682.